Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 1.00 |
| ▸ | ABL1 | P00519 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 4/20 | 1.00 |
| ▸ | FYN | P06241 | 4/20 | 1.00 |
| ▸ | CSK | P41240 | 3/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 1/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.64 |
| ▸ | PRKDC | P78527 | 1/20 | 0.64 |
| ▸ | PRKACA | P17612 | 3/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389632 | 1.00 | SRC (1.00) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL29379380 | 1.00 | SRC (1.00) | SRCABL1PRKD3PRKD2PRKD1 | |
| Hydrochloric Acid SCHEMBL7037036 | 0.99 | SRC (0.98) | SRCABL1PRKD3PRKD2PRKD1 | |
| Hydrochloric Acid SCHEMBL30682158 | 0.99 | SRC (0.98) | SRCABL1PRKD3PRKD2PRKD1 | |
| Hydrochloric Acid SCHEMBL31031035 | 0.99 | SRC (0.98) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL12551746 | 0.85 | SRC (0.74) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL13019875 | 0.84 | SRC (0.73) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL12551755 | 0.84 | SRC (0.73) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL3611430 | 0.84 | SRC (0.72) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL12551780 | 0.82 | SRC (0.70) | SRCABL1PRKD3PRKD2PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041603-A1 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | NESTLE SA (CH) | 2022-02-10 | — | — | US | claimed |
| EP-3852763-A1 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2021-07-28 | — | — | EP | claimed |
| CN-112566639-A | SRC inhibitor compounds for skeletal muscle modulation, methods and uses thereof | 雀巢产品有限公司 | 2021-03-26 | — | — | CN | claimed |
| US-10913932-B2 | Maturation of mammalian hepatocytes | TAKARA BIO EUROPE AB (SE) | 2021-02-09 | — | — | US | claimed |
| WO-2020058072-A1 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2020-03-26 | — | — | WO | claimed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | claimed |
| US-9730926-B2 | Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-08-15 | — | — | US | claimed |
| EP-2528919-B1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIV WASHINGTON (US) | 2016-11-02 | — | — | EP | claimed |
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-08-06 | — | — | US | claimed |
| EP-2400033-B1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORP (JP) | 2013-02-20 | — | — | EP | claimed |
| US-20110318768-A1 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT | SYSMEX CORPORATION (JP) | 2011-12-29 | — | — | US | claimed |
| US-20070087982-A1 | Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences | OREGON HEALTH & SCIENCE UNIVERSITY | 2007-04-19 | — | — | US | claimed |
| EP-1648997-A2 | METHODS OF TREATMENT AND DISGNOSIS USING MODULATORS OF VIRUS-INDUCED CELLULAR GENE SEQUENCES | Oregon Health and Science University (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005010143-A2 | METHODS OF TREATMENT AND DISGNOSIS USING MODULATORS OF VIRUS-INDUCED CELLULAR GENE SEQUENCES | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2005-02-03 | — | — | WO | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| EP-1140938-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | Princeton University (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042042-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | PRINCETON UNIVERSITY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | SRC 1968/4885ABL1 785/4885PRKD3 1651/4885 |
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SRC, MET, EGFR | SRC 1/4885ABL1 13/4885PRKD3 1216/4885 |
| US-20220041603-A1 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | MYLK2, MUSK, SRC | SRC 3/4885ABL1 316/4885PRKD3 94/4885 |
| US-20070087982-A1 | Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences | HAVCR2, HMGB3, HMGB2 | SRC 24/4885ABL1 37/4885PRKD3 2752/4885 |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885PRKD3 58/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | SRC 1968/4885ABL1 785/4885PRKD3 1651/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | SRC 4421/4885ABL1 3418/4885PRKD3 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.